Skip to content
Precision for Medicine
Contact Us
false false
Category Hero Image image 35

Execute Clinical Trial Feasibility with Precision

Optimize your study's initiation through precise country and site selection, powered by actionable insights.
At Precision, our feasibility process is more than just a preliminary step; it's a critical foundation for the success of your clinical trial. By focusing on strategic site selection and in-depth insights gathering, we ensure your study starts with a significant advantage. 
iStock-876250496

Plan for success with Site Feasibility

Site feasibility is the cornerstone of clinical trial planning, acting as the bridge between groundbreaking research and its successful execution. Understanding the pivotal role of site feasibility ensures a solid foundation for any clinical study. It's not merely about identifying potential sites but about strategic alignment with the trial's objectives, patient populations, and operational capacities. This proactive approach to site selection, grounded in data-driven insights and comprehensive evaluations, mitigates risks and sets the stage for successful patient enrollment and study outcomes.

Roughly 80% of clinical trials fail to meet original enrollment timelines, and about one-third of Phase III study terminations are due to enrollment difficulties. Additionally, 15% to 20% of sites never enroll a single patient.

Given these statistics, it's evident that conducting a comprehensive feasibility study is essential for avoiding common pitfalls like poor enrollment and sites that never enroll.  Precision's feasibility team employs multiple methods to ensure a sponsor's needs are met, tailoring our approach to each unique trial. This adaptability, combined with a deep understanding of the intricacies of clinical trials, allows Precision to navigate complex requirements and ensure trials are set up for success from the start.

Precision's Clinical Trial Feasibility process overview

Step 1

Initial Planning
  • Understand study objectives
  • Identify target countries/sites
  • Develop feasibility questionnaire
  • Augment site list with Precision/external data
  • Site list finalized for feasibility start

Step 2

Data Collection & Analysis
  • Distribute questionnaires
  • Pursue sites for response
  • Collect sites responses
  • Evaluate sites performance
  • Prepare feasibility report
  • Review report with client
  • Filter out low-potential sites

Step 3

Recruitment Modeling
  • Develop enrollment scenarios
  • Estimate recruitment timelines
  • Project patient numbers
  • Adjust site requirements
  • Plan for contingencies
  • Present models to clients

Step 4

Site Selection & Verification
  • Confirm top-performing sites
  • Schedule pre-study visits
  • Verify site infrastructure
  • Assess staff expertise
  • Determine recruitment potential
  • Finalize site list for activation
  • Finalize back-up site list

Step 5

Performance Monitoring
  • Regular progress check-ins
  • Address emerging issues
  • Adjust recruitment plans
  • Activate backup sites
  • Ensure timeline adherence
  • Provide ongoing support

Precision’s strategic approach to clinical trial feasibility

Our approach to site feasibility is both comprehensive and meticulous. By integrating broad data analysis with site-specific insights, we ensure each trial starts on the best possible footing. Our process begins with understanding study objectives and identifying optimal countries and sites, followed by developing and distributing targeted feasibility questionnaires. We then analyze site responses and performance, preparing detailed feasibility reports for client review. Through recruitment modeling, we project patient numbers and timelines, allowing for adjustments and contingency planning. Site selection is confirmed through pre-study visits and infrastructure verification, with backup sites identified for risk mitigation. Continuous performance monitoring ensures adherence to timelines and proactive issue resolution, backed by ongoing support. This strategic and detailed approach enables our sponsors to navigate trial complexities with confidence, ensuring successful study execution.

Our site feasibility services can be executed during pre-study phases or integrated into full study start-up processes. This flexibility allows us to adapt to each sponsor's unique requirements, providing tailored support that aligns with their specific clinical trial needs.

Insights from Precision’s experts

Stay ahead with the latest insights from Precision’s team of experts. Discover valuable perspectives, updates, and strategies to navigate early and late phase development. 

Explore our blog
Read: Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM) Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

Clinical Trials

Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1748379090824, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Kurt Preugschat avatar

    Kurt Preugschat
Discover
Read: Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM) Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

Clinical Trials

Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1748379090824, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Kurt Preugschat avatar

    Kurt Preugschat
Discover
Read: Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial

Clinical Trials

Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=187570680222, hs_child_table_id=0, hs_updated_at=1742413198455, hs_published_at=1748379090824, description=Christine has been ensuring high performance delivery of clinical research projects for more than 23 years. During this time, she has successfully led diverse teams across various cancer indications including renal, pancreatic, melanoma, lung, head and neck, breast, multiple myeloma, extra-nodal NK/T lymphoma, non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma. Within the CRO setting she also supported the strategic development of over 50 hematology/oncology programs including complex Phase 1 projects in immuno-oncology and autologous cell therapy. She also led the establishment of a novel oncology research infrastructure which accelerated study activations for Phase 1 solid tumor studies. Christine obtained her master’s degree in public health at the University of Texas where she also trained in the development and implementation of clinical and epidemiologic research at the Coordinating Center for Clinical Trials as well as the Center for Occupational and Environment Health., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Christine%20Lusk-1.png',altText='Christine Lusk-1',fileId=187579105870}, lastname=Lusk, hs_initial_published_at=1742410730688, hs_created_by_user_id=26433386, hs_created_at=1742410650472, hs_is_edited=false, hs_deleted_at=0, name=Christine, job=Director, Project Management, slug=christine-lusk, hs_updated_by_user_id=51739740}, second={hs_id=190691157084, hs_child_table_id=0, hs_updated_at=1748379058655, hs_published_at=1748379090824, description=Over the last 15 years, Megan has played a key role in advancing multiple oncology compounds through various stages of development, across numerous tumor types. Having worked at both biotech and CRO companies, Megan brings a comprehensive understanding of clinical operations and drug development. Megan maintains a focus on accelerating the development of innovative cancer therapies to improve patient outcomes worldwide., avatar=Image{width=3024,height=4032,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Megan%20Knoch.jpg',altText='Megan Knoch',fileId=190688034156}, lastname=Knoch, hs_initial_published_at=1748379090824, hs_created_by_user_id=26433386, hs_created_at=1748379018316, hs_is_edited=false, hs_deleted_at=0, name=Megan, slug=megan-knoch, hs_updated_by_user_id=26433386}, third={}})
  • Christine L. avatar

    Christine L.
  • Megan K. avatar

    Megan K.
Discover

Advance therapeutic breakthroughs with Precision

Explore the breadth of our expertise in therapeutics and modalities, as we lead your novel treatments in Oncology, Rare Diseases and beyond, from the groundbreaking idea to clinical realization.

Oncology Explore Rare diseases Explore Autoimmune Explore Gene Therapy Explore Cell Therapy Explore

Clinical trial excellence: Precision in all phases

With people across 70+ countries, our team provides comprehensive clinical trial services that streamline and accelerate drug development at a global scale

  • Explore

    Early Phase Excellence

    Embark on the critical first steps of clinical discovery with our expertly managed early phase trials, where meticulous attention meets innovative strategy.
    Explore
  • Explore

    Late Phase Success

    Discover the path to market with our Late Phase Development expertise – delivering precision, scale, and efficiency for your clinical journey.
    Explore

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore